GOLDMAN SACHS GROUP INC - PROTAGONIST THERAPEUTICS INC ownership

PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 139 filers reported holding PROTAGONIST THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 2.23 and the average weighting 0.5%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of PROTAGONIST THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$7,792,946
-49.5%
467,203
-16.5%
0.00%
-33.3%
Q2 2023$15,445,380
+46.2%
559,210
+21.7%
0.00%
+50.0%
Q1 2023$10,567,350
+57.1%
459,450
-25.5%
0.00%0.0%
Q4 2022$6,728,459
+5.4%
616,724
-18.5%
0.00%
+100.0%
Q3 2022$6,382,000
+27.7%
757,079
+19.8%
0.00%0.0%
Q2 2022$4,999,000
-39.0%
631,916
+82.4%
0.00%
-50.0%
Q1 2022$8,201,000
+94.0%
346,359
+180.2%
0.00%
+100.0%
Q4 2021$4,228,000
-43.6%
123,629
-70.8%
0.00%
-50.0%
Q3 2021$7,499,000
-57.4%
423,195
+8.0%
0.00%
-50.0%
Q2 2021$17,590,000
+64.0%
391,943
-5.4%
0.00%
+33.3%
Q1 2021$10,727,000
-3.6%
414,134
-24.9%
0.00%0.0%
Q4 2020$11,124,000
+156.2%
551,787
+148.5%
0.00%
+200.0%
Q3 2020$4,342,000
-53.6%
222,080
-58.1%
0.00%
-66.7%
Q2 2020$9,361,000
+1984.9%
530,048
+732.1%
0.00%
Q1 2020$449,000
+216.2%
63,701
+216.3%
0.00%
Q4 2019$142,000
-92.5%
20,139
-87.2%
0.00%
-100.0%
Q3 2019$1,885,000
+547.8%
156,961
+552.3%
0.00%
Q2 2019$291,000
-77.1%
24,061
-76.2%
0.00%
Q1 2019$1,269,000
+575.0%
100,992
+260.7%
0.00%
Q4 2018$188,000
-53.6%
27,999
-28.9%
0.00%
Q3 2018$405,000
-27.3%
39,369
-52.5%
0.00%
Q2 2018$557,000
+108.6%
82,864
+166.7%
0.00%
Q1 2018$267,000
-56.6%
31,069
+5.1%
0.00%
Q4 2017$615,000
+118.1%
29,563
+121.6%
0.00%
Q3 2016$282,00013,3400.00%
Other shareholders
PROTAGONIST THERAPEUTICS INC shareholders Q2 2021
NameSharesValueWeighting ↓
JOHNSON & JOHNSON 2,449,183$56,331,20918.32%
Kynam Capital Management, LP 1,375,000$31,625,0004.08%
BVF INC/IL 3,775,900$86,845,7003.18%
Cormorant Asset Management, LP 1,700,000$39,1002.58%
RTW INVESTMENTS, LP 4,600,799$105,818,3772.20%
Ghost Tree Capital, LLC 225,000$5,175,0001.53%
683 Capital Management, LLC 791,000$18,193,0001.36%
Ikarian Capital, LLC 211,400$4,862,2001.10%
Ikarian Capital, LLC 211,400$4,862,2001.10%
SILVERARC CAPITAL MANAGEMENT, LLC 105,486$2,426,1781.00%
View complete list of PROTAGONIST THERAPEUTICS INC shareholders